REKOMBINANTES ALPHA-INTERFERON(a-IFN) BEI PROGRESSIVER HARRZELL-LEUKAMIE: EINE STUDIE BEI VORHER NICHT BEHANDELTEN UND NICHT SPLENEKTOMIERTEN PATIENTEn

I. Schwarzinger, P. Bettelheim, A. Chott, Ch Herold, W. Hinterberger, U. Koller, M. Kos, E. Neumann, Th Radaszkiewicz, K. Lechner

Research output: Contribution to journalArticle

Abstract

Ten nonsplenectomized patients (5 males, 5 females) with hairy-cell leukemia were treated with recombinant alpha-IFN. The median age of patients was 54 years (32-76 years). The time between diagnosis and onset of treatment ranged from 1-120 months. Initially the patients received 5 x 106 I.U. daily by intramuscular or subcutaneous injections for 10 weeks. Thereafter the dose of IFN was reduced to 5 x106 I.U.3 x weekly and after 6 months to 5 x 1106 I.U. 2 x weekly for at least 6 months. The median time of patient follow-up is 23 months (4-28 months). Three complete remissions were achieved after 3-24 months and five partial remissions after 4-18 months. One patient showed improvement after 3 months, and one patient died from cerebral hemorrhage after 5 weeks. In eight of ten patients peripheral blood cell counts normalized after a median of 7 months (1.5-11 months). A marked reduction in spleen size was observed in all seven patients who had splenomegaly at study entry. Two of three patients who interrupted therapy have relapsed after 2 and 6 months. We conclude that alpha-interferon is an effective method of first-line treatment in patients with HCL.

Original languageEnglish (US)
Pages (from-to)47-51
Number of pages5
JournalWiener Klinische Wochenschrift
Volume100
Issue number2
StatePublished - Jan 1 1988

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'REKOMBINANTES ALPHA-INTERFERON(a-IFN) BEI PROGRESSIVER HARRZELL-LEUKAMIE: EINE STUDIE BEI VORHER NICHT BEHANDELTEN UND NICHT SPLENEKTOMIERTEN PATIENTEn'. Together they form a unique fingerprint.

  • Cite this

    Schwarzinger, I., Bettelheim, P., Chott, A., Herold, C., Hinterberger, W., Koller, U., Kos, M., Neumann, E., Radaszkiewicz, T., & Lechner, K. (1988). REKOMBINANTES ALPHA-INTERFERON(a-IFN) BEI PROGRESSIVER HARRZELL-LEUKAMIE: EINE STUDIE BEI VORHER NICHT BEHANDELTEN UND NICHT SPLENEKTOMIERTEN PATIENTEn. Wiener Klinische Wochenschrift, 100(2), 47-51.